Epirium’s 15-PGDH inhibitor IBD candidates improve disease outcomes in models

Epirium Bio Inc. has developed a series of small-molecule 15-PGDH inhibitors, the phase II-ready MF-300 and preclinical candidate MF-1305, as potential therapeutics for inflammatory bowel disease (IBD).